Community Participation in National Health Programs

Definition

"The process by which individuals and families assume responsibility for their own health and welfare and for those of the community, and develop the capacity to contribute to their and the community's development."

• Park's Textbook of Preventive and Social Medicine, p. 811-822

Historical Background

• Mere socialization of medicine (e.g., nationalization of health services as in UK 1946, Soviet Union) was found insufficient to ensure utilization of health services. Community participation was recognized as the missing element.
• The Declaration of Alma-Ata (1978) was the landmark document that formally embedded community participation as a pillar of global health policy, giving it "a new meaning and direction."
• It called on governments to formulate national policies and plans to launch Primary Health Care (PHC) as part of their national health systems.
• The Ottawa Charter (1986) further reinforced community participation as a core principle of health promotion.

Why Community Participation is Essential

1. Universal coverage is impossible without it - no country can achieve PHC goals without involvement of local communities
2. Local resource mobilization - manpower, money, and materials at the grassroots level
3. Cultural acceptability - health workers from the community overcome cultural and communication barriers
4. Equity - shifts the center of gravity of healthcare from urban elite to rural underserved populations
5. Demedicalization of health - shifts health from being a service for people to a responsibility of people
6. Sustainability - community-driven programs are more self-reliant and durable

"The war against disease and for health cannot be fought by physicians alone. It is a people's war in which the entire population must be mobilized permanently." - Henry Sigerist (medical historian)

Three Ways a Community Can Participate

• Park's Textbook, p. 1829

Community Participation in Primary Health Care (PHC)

1. Social equity
2. Nationwide coverage
3. Self-reliance
4. Intersectoral coordination
5. Community participation in planning and implementation

Community Participation in India's National Health Programs

Key Community-Level Workers

National Programs Using Community Participation

• National Health Mission (NHM) - ASHA is the backbone of community outreach
• National Mental Health Programme (1982) - launched to ensure mental health care for the community at risk and underprivileged sections
• MCH/FP services - now integral parts of PHC with emphasis on community participation and intersectoral coordination (National Health Policy 2002, National Population Policy 2000)
• Disease control programs (TB, malaria, leprosy, STDs) - PHC framework with community participation, political support, and intersectoral coordination
• Health for All (HFA) by 2000 AD and now the Sustainable Development Goals (SDGs) - framed around community-based approaches

Levels of Health Care and Community Participation

Barriers to Community Participation

1. Social fragmentation - caste and religious divisions (especially in India) obstruct complete participation
2. Professional resistance - historically, the greatest resistance came from the medical profession itself, not the lay public
3. Lack of community awareness - limited health literacy
4. Political and administrative inertia - lack of genuine political will
5. Cultural heterogeneity - no single standard pattern of community participation can be universally applied; flexibility of approach is essential
6. Urban bias in health resource distribution - three-quarters of health budgets spent in cities, three-quarters of the population in rural areas

"Community participation has become an aphorism that is still awaiting genuine realization in many countries of the world." - Park's Textbook, p. 1831

"Deprofessionalization" of Medicine

• Educator
• Case-finder
• Preventive care provider
• Counsellor
• Agent of social change

Intersectoral Coordination - The Necessary Partner

• Agriculture and animal husbandry
• Food and nutrition
• Industry and housing
• Education
• Public works and communication

Key Declarations and Milestones

• Park's Textbook of Preventive and Social Medicine (primary source throughout)

Epidemiology of Ebola Virus Disease (EVD)

1. The Virus - Classification and Species

Morphology of the filovirus virion - Sherris & Ryan's Medical Microbiology

• Sherris & Ryan's Medical Microbiology, 8th Ed.; Goodman & Gilman's

2. Historical Discovery and First Outbreaks

• 1976 - Two simultaneous outbreaks:
  • Northern Zaire (DRC): CFR ~90% (Zaire strain)
  • Southern Sudan: CFR ~50% (Sudan strain)
  • These were initially thought to be the same virus; later shown to be antigenically distinct
• 1967 - Marburg virus (sister filovirus) first described in Germany/Yugoslavia from African monkeys; foundational event for understanding filoviruses
• 1990 - Reston ebolavirus isolated from Philippine monkeys in a U.S. quarantine facility; non-pathogenic in humans
• 1994 - Tai Forest (Ivory Coast) strain identified; single scientist infected from chimpanzee autopsy, survived

3. Major Outbreaks - Chronology

The 2014-2016 West Africa Epidemic (Largest in History)

• Harrison's Principles of Internal Medicine, 22nd Ed. (2025); Rosen's Emergency Medicine

2018-2020 DRC Outbreak (Second Largest)

Other DRC Outbreaks

• 2017: 8 cases, 4 deaths (CFR 61%)
• 2020: 138 cases, 55 deaths (CFR 42.3%)

2025 Outbreaks (Most Recent)

• DRC - 16th outbreak (declared September 4, 2025): Bulape Health Zone, Kasai Province; 64 cases (53 confirmed, 11 probable), 45 deaths, CFR 70.3% (as of November 2025) - a new spillover event from unknown reservoir
• Uganda (declared January 30, 2025): Sudan virus strain in Kampala - notable because no approved vaccine exists for Sudan strain

4. Geographic Distribution

• Outbreaks confined primarily to sub-Saharan Africa, especially the DRC (formerly Zaire)
• DRC has experienced the most outbreaks - 16 as of 2025
• Other affected countries: Uganda, Sudan, Gabon, Republic of Congo, Guinea, Liberia, Sierra Leone
• The DRC remains the epicenter due to high biodiversity, rainforest habitat, and contact with wildlife

5. Reservoir and Zoonotic Transmission

• Filoviruses are zoonotic - spillover from infected animals to humans initiates outbreaks
• Infected animals include: fruit bats, non-human primates (apes, monkeys), and duikers (antelope)
• The primary route of zoonotic transmission is unknown - contact with bat droppings, eating infected bush meat, or handling infected primates are suspected routes
• The Bombali ebolavirus species has been identified directly in bats without causing human disease

6. Mode of Transmission (Human-to-Human)

• Direct contact with blood or body fluids (urine, saliva, sweat, feces, vomit, breast milk, semen) of infected, sick, or deceased persons
• Sexual transmission (oral, vaginal, anal) - demonstrated epidemiologically
• Fomite transmission via contaminated needles, syringes, clothing, or bedding
• Unsafe burials - deceased EVD patients are highly infectious; traditional burial practices (washing/touching the body) have driven major transmission chains
• Nosocomial (healthcare-associated) transmission - a critical amplifier, especially in settings lacking PPE

Individuals are not contagious until they develop symptoms. This is an important epidemiological distinction that supports the feasibility of contact tracing.

7. Incubation Period

• Range: 2 to 21 days (average 4-10 days)
• The 21-day period is used for surveillance and quarantine purposes

8. Case Fatality Rate (CFR)

• Overall range: 25% to 90% across outbreaks
• Average: ~50% (historically)
• Zaire strain: 50-95% (highest)
• Sudan strain: ~50%
• CFR varies significantly by:
  • Quality of supportive care available
  • Access to specific treatments (monoclonal antibodies)
  • Timing of diagnosis
  • Health system capacity
• In settings with quality supportive/critical care, outcomes are demonstrably better - affirming EVD is treatable even without antivirals

9. Clinical Features (Brief)

10. Pathogenesis (Brief)

• Ebola infects and lyses monocytes, macrophages, dendritic cells, and reticuloendothelial cells
• Release of inflammatory cytokines damages vascular integrity - leading to hemorrhage and shock
• The glycoprotein (GP) on the viral envelope mediates attachment and entry into host cells - it is the target of approved monoclonal antibody therapies

11. Diagnosis

• RT-PCR on plasma specimen: current gold standard
• Rapid antigen point-of-care test: 15-minute turnaround; good sensitivity/specificity compared to RT-PCR
• Laboratory findings: thrombocytopenia, anemia, coagulopathy, elevated transaminases, elevated creatinine, hypocalcemia, hypokalemia
• Testing should only be done for patients meeting both exposure history and clinical criteria
• Malaria testing (thick and thin blood smear) is mandatory - it is far more common in endemic areas

12. Prevention and Treatment

Vaccines

• rVSV-ZEBOV (Ervebo) - FDA-approved 2019; live attenuated recombinant VSV vector expressing Zaire ebolavirus glycoprotein; single IM dose; deployed using ring vaccination strategy in DRC 2018-2020
  • Indicated for persons 18+ who are: outbreak responders, workers at Ebola treatment centers, or BSL-4 lab workers
  • Only covers Zaire strain - no approved vaccine for Sudan or other strains (a major gap in the 2025 Uganda outbreak)

Specific Treatments (FDA-approved for Zaire ebolavirus)

1. Inmazeb (atoltivimab + maftivimab + odesivimab) - cocktail of 3 recombinant human IgG1 mAbs targeting Zaire GP
2. Ebanga (ansuvimab) - single mAb targeting Zaire GP

Infection Control

• Strict PPE (full barrier precautions)
• Safe burial practices
• Isolation of suspected/confirmed cases
• Contact tracing and quarantine (21-day window)
• Decontamination of fomites

13. Factors Driving Outbreaks

1. Weak health systems - inadequate PPE, no running water, no labs
2. Unsafe burials - cultural practices involving contact with the deceased
3. Healthcare amplification - poor infection control
4. Community mistrust - of health workers and authorities; impedes surveillance
5. Armed conflict - hampers response in DRC (2018-2020)
6. Lack of vaccines for non-Zaire strains - especially Sudan strain
7. Delayed diagnosis - nonspecific early presentation
8. Urban spread - 2014-2016 marked the first major urban epidemic

A 2025 systematic review and meta-analysis (PMID 41219638) from Uganda found that diagnostic delays and slow response timeliness significantly increased outbreak-level case-fatality ratios.

Summary Table

• Virus - Filoviridae family, negative-sense ssRNA, 6 species
• Reservoir - Fruit bats (probable)
• Transmission - Body fluids, unsafe burials, nosocomial, sexual
• Incubation - 2-21 days (avg 4-10)
• CFR - 25-90% (avg ~50%); Zaire strain highest (up to 95%)
• Biggest outbreak - 2014-2016 West Africa: 28,652 cases, 11,325 deaths
• Most outbreaks - DRC (16 outbreaks as of 2025)
• Human-pathogenic species - Zaire, Sudan, Bundibugyo, Tai Forest
• Vaccine - Ervebo (Zaire only, ring vaccination strategy)
• Treatment - Inmazeb & Ebanga (monoclonal antibodies, Zaire only)
• Key rule - NOT infectious before symptom onset (supports contact tracing)